/PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the outcome of the U.S. Food and Drug...
AI in Psychiatry: Changing the Landscape of Mental Health Care psychiatrictimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatrictimes.com Daily Mail and Mail on Sunday newspapers.
An Update on Personality Disorders and Common Comorbidities psychiatrictimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatrictimes.com Daily Mail and Mail on Sunday newspapers.
Neuropsychiatric disorders regularly occur following traumatic brain injury and are often diagnosed within the first year postinjury. Diagnosis and treatment of neuropsychiatric disorders can be difficult due to a number of interacting factors, such as preinjury psychiatric history, lesion location, injury severity, substance misuse, and psychosocial complications. Clinicians should use a highly individualized approach to diagnosis and treatment planning.
Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.
Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Naturally occurring variations in appointment frequencies do not appear to have a major impact on clinical outcomes, but they significantly affect waiting times.